Route of administration and chemical structure. MK-677 is non-peptide small molecule (spiropiperidine core), orally active and resistant to degradation in the gastrointestinal tract – unlike peptide GHRPs (GHRP-2, GHRP-6, ipamorelin, hexarelin), which are short peptides degraded in the gastrointestinal tract and administered parenterally in studies. Both families act on the same ghrelin receptor (GHS-R1a) and stimulate the release of endogenous GH, but MK-677 is distinguished by oral bioavailability and long half-life (~24 h). The observations are within the research context and do not constitute a suggestion for use of the RUO reagent in humans.
MK677 60 caps
MK-677 (ibutamoren) 10 mg × 60 caps is a non-peptide, orally active growth hormone secretagogue from the Endogenic line – a small molecule acting as an agonist of the ghrelin receptor (GHS-R1a). It stimulates the pituitary gland to pulsatile release of endogenous GH with a secondary increase in IGF-1, maintaining the physiological rhythm of secretion – unlike exogenous rhGH. Test reagent
MK-677 (Ibutamoren) 10 mg 60 caps - ghrelin mimetic, research reagent
- MK-677 (ibutamoren): a non-peptide ghrelin receptor (GHS-R1a) agonist.
- 10 mg per capsule; pack of 60 capsules.
- Research Use Only reagent, not a medicinal product.
Product status information
Chemical reagent intended exclusively for laboratory tests (Research Use Only). It is not a medicinal product, dietary supplement or food. It is not intended for use on humans or animals. Sales only to registered research units and laboratories.
WADA STATUS – CATEGORY S2 (PEPTIDE HORMONES, GROWTH FACTORS AND MIMETICS)
MK-677 (ibutamoren) is on the World Anti-Doping Agency (WADA) Prohibited List in the category S2 – peptide hormones, growth factors, related substances and mimetics, a subgroup of growth hormone secretagogues (GH secretagogues). The substance is prohibited at all times, both in competition and out of competition. It is imperative that Registered Athletes (ADAMS) verify the current Prohibited List before any decision – the presence of ibutamoren or its metabolites in a doping sample constitutes an anti-doping rule violation.
Introduction
The somatotropic axis – the hypothalamic-pituitary-liver coupling regulating the secretion of growth hormone (GH) and secondary insulin-like growth factor 1 (IGF-1) – has remained one of the most difficult areas of experimental endocrinology for decades. Exogenous recombinant growth hormone (rhGH) increases GH levels rapidly and beyond the physiological rhythm, abolishing the natural pulsatility of secretion.
Pharmacology therefore looked for molecules that would stimulate the pituitary gland to release them own GH – with preservation of pulsatile rhythm and feedback. This class was called growth hormone secretagogues (GH secretagogues). MK-677, also known as ibutamoren, is one of the best characterized representatives of this class. Pro-Body supplies it in line Endogenic as a research reagent in format 10 mg × 60 capsules.
Chemically it is this small non-peptide molecule — unlike peptide secretagogues (GHRP-2, GHRP-6, ipamorelin), which are administered parenterally in studies. In terms of mechanism, it is ghrelin receptor agonist (GHS-R1a): mimics the action of ghrelin, stimulating the pulsatile release of GH from the anterior pituitary, and secondarily increasing the level of IGF-1. MK-677 (research code MK-0677) was developed in Merck laboratories in the 1990s as an orally active ghrelin mimetic.
The compound has undergone clinical trials in the context of sarcopenia, GH deficiency and catabolism, but has not been registered as a drug. In research terms, it remains a model tool for studying the GH–IGF-1 axis, ghrelin receptor signaling, appetite regulation, sleep architecture and nitrogen metabolism. Purity verified by HPLC ≥98%, identity confirmed by mass spectrometry, COA available for each batch.
REGULATORY STATUS
MK-677 (ibutamoren) is not registered as a drug in the EU or the USA – it remains a compound at the research stage (clinical phase II for sarcopenia), without authorization by EMA, FDA or EFSA. MK-677 is on the WADA Prohibited List in category S2 (growth hormone secretagogue) – permanently prohibited. Communication of the product as an “over the counter GH booster”, “muscle gainer” or “growth hormone stimulator” is contrary to the Research Use Only framework.
Ghrelin, GHS-R receptor and growth hormone secretagogues
Ghrelin is a peptide hormone produced mainly in the stomach, commonly known as the “hunger hormone”. It works through a G protein-coupled receptor called GHS-R1a (growth hormone secretagogue receptor type 1a). This receptor was identified during the search for a molecular target for synthetic GH secretagogues – and only later was its natural ligand, ghrelin, discovered.
Stimulation of GHS-R1a in the pituitary gland triggers a cascade leading to the release of growth hormone; the same receptor in the hypothalamus is involved in the regulation of appetite, and in other tissues – in the modulation of sleep and metabolism. Growth hormone secretagogues are a class of compounds that stimulate the pituitary gland to secrete endogenous GH, instead of supplying the hormone from outside.
This makes them a common reference point in research on peptides that increase growth hormone. They are divided into two main families. The first is peptide GHRP (growth hormone releasing peptides) – GHRP-2, GHRP-6, ipamorelin, hexarelin – short peptides administered parenterally in studies because they are degraded in the gastrointestinal tract. The second one is non-peptide, orally active small molecules, the model representative of which is the MK-677.
Both families act on the same receptor (GHS-R1a), but differ in chemical structure, route of administration and pharmacokinetics. The world of pharmacology is keeping an eye on MK-677 for several reasons. First, as a model oral ghrelin mimetic – a tool for examining the somatotropic axis by the oral route. Secondly, as a compound with a long half-life (~24 h), which allows examining the effects of maintaining an increased GH drive while maintaining the pulsatile rhythm.
Third, as a GHS-R1a ligand useful in studies of appetite regulation, sleep architecture, and nitrogen balance – functions in which ghrelin signaling is involved.
What is MK-677?
Chemically, MK-677 is a small non-peptide molecule – a spiropiperidine ghrelin receptor agonist, available as the free base or mesylate salt.
- Common name: MK-677, ibutamoren, ibutamoren mesylate
- Research code: MK-0677
- Systematic name: spiropiperidine derivative with a non-peptide structure (ghrelin mimetic)
- Pharmacological class: non-peptide ghrelin receptor agonist (GHS-R1a); orally active growth hormone secretagogue (GH secretagogue); ghrelin mimetic
- CAS number: 159752-10-0 (free base); 159634-47-6 (mesylate) – with uncertainty “to be verified with batch COA”
- Molecular formula: C₂₇H₃₆N₄O₅S (to be verified in the batch COA)
- Molar mass: ~528.67 g/mol (to be verified in the batch COA)
- Laboratory of Origin: Merck Research Laboratories; developed in the 1990s as an oral ghrelin mimetic
- Delivered form: hard capsule, 10 mg of active substance per capsule, 60 capsules; pharmaceutical grade ≥98% HPLC
Table of physicochemical characteristics
| Parameter | Value | Note |
|---|---|---|
| Name | MK-677 (ibutamoren), MK-0677 | mesylate: ibutamoren mesylate |
| Systematic name | spiropiperidine derivative (ghrelin mimetic) | non-peptide structure |
| Chemical class | small non-peptide molecule | not a peptide, not a SARM |
| Pharmacological class | GHS-R1a agonist, oral GH secretagogue | ghrelin mimetic |
| CAS | 159752-10-0 (base); 159634-47-6 (mesylate) | for verification in the batch COA |
| Molecular formula | C₂₇H₃₆N₄O₅S | for verification in the batch COA |
| Molar mass | ~528.67 g/mol | for verification in the batch COA |
| Purity | ≥98% HPLC | UV detection, per batch verification |
| Form | capsule, 10 mg/capsule, 60 capsules | — |
| Molecular target | ghrelin receptor GHS-R1a (pituitary, hypothalamus) | pulsatile GH release |
| Half-life | ~24 h (long T½) | oral activity |
| Clinical status | phase II (sarcopenia studies), unregistered | no EU/US registration |
| WADA status | Prohibited List, Category S2 (GH secretagogues) | prohibited permanently |
Mechanism of action at the molecular level
MK-677 acts in research models through a single central receptor mechanism that gives rise to several related pharmacological observations. The common denominator is stimulation of the ghrelin receptor and secondary activation of the somatotropic axis. Pharmacological profile observed in studies:
- Ghrelin receptor agonism (GHS-R1a) – ghrelin mimetic. Central mechanism MK-677. The molecule binds the GHS-R1a receptor in the anterior pituitary and hypothalamus, mimicking the action of natural ghrelin. Stimulation of the receptor in the pituitary triggers a signaling cascade (phospholipase C pathway, mobilization of intracellular calcium), leading to pulsatile release of growth hormone from somatotropic cells (Patchett et al. 1995). This is the original, direct molecular effect from which the remaining observations arise.
- Secondary increase in IGF-1. Increased GH drive stimulates the liver to produce insulin-like growth factor 1 (IGF-1), the primary mediator of the peripheral effects of growth hormone. In studies with MK-677, sustained increases in both GH and IGF-1 levels were observed (Chapman et al. 1996, Murphy et al. 1998). The GH–IGF-1 axis is the main molecule of research interest.
- Oral activity and long half-life (~24 h). The most important feature that distinguishes MK-677 from peptide GHRPs. As a small non-peptide molecule, the compound is resistant to degradation in the gastrointestinal tract and has oral bioavailability – unlike GHRP-2, GHRP-6 or ipamorelin, which are degraded and administered parenterally in studies. The long half-life (~24 h) allows testing the effects of maintaining an increased GH drive with a single daily exposure.
- Maintaining the pulsatility of GH secretion. A feature that distinguishes the secretagogue from exogenous rhGH. MK-677 stimulates the pituitary gland to release own GH while maintaining the physiological pulsatile rhythm and feedback of the somatotropic axis – unlike recombinant growth hormone, which increases GH levels rapidly and outside the natural rhythm. This makes the MK-677 a useful tool for examining axle adjustments while maintaining its architecture.
- Impact on appetite, deep sleep and nitrogen metabolism. Ghrelin signaling is involved in the regulation of appetite (orexigenic effects), sleep architecture (slow-wave sleep component), and nitrogen balance. In studies on MK-677, an effect on these parameters was observed, consistent with the profile of a ghrelin receptor agonist – directions important in models of catabolism, sarcopenia and regeneration.
IMPORTANT DISTINCTION
“Stimulation of GH secretion, increase in IGF-1, effect on appetite and sleep” in the context of this description refer only to observations in studies (clinical phase I/II, preclinical models). This is not a guarantee or suggestion of effect in humans using the RUO reagent. The most important pharmacological distinctions: first, MK-677 is small oral molecule – not a peptide and not an androgenic SARM — works through the ghrelin receptor (GHS-R1a), not through the androgen receptor (like SARMs) or as a peptide administered parenterally.
Secondly, there is MK-677 secretary (stimulates the secretion of its own GH while maintaining pulsation), and not exogenous growth hormone – it differs from recombinant rhGH, which supplies the hormone from the outside outside the physiological rhythm. Third, this variant is capsules 10 mg, a separate format from the solution available from Pro-Body MK-677 in liquid form 30 ml.
In the context of research safety, the literature indicates possible water retention and an increase in glycemia and insulin resistance as observations that need to be taken into account when designing models. Compound remains a research tool.
Important distinction - GH secretagogue and exogenous rhGH, peptide and SARM
Understanding MK-677’s position on the pharmacological map is the focal point of this brief:
- Secretagogue and exogenous rhGH — MK-677 does not provide growth hormone from the outside. It stimulates the pituitary gland to release endogenous GH through the ghrelin receptor, maintaining the pulsatile rhythm of secretion and feedback. Exogenous recombinant rhGH increases GH levels dramatically and abolishes the natural rhythm. This is a qualitative difference: one molecule “turns on its own production”, the other “supplies the ready-made hormone”.
- Small molecule and peptide — MK-677 is a non-peptide small molecule (spiropiperidine core), orally active and resistant to degradation in the gastrointestinal tract. Peptide secretagogues such as GHRP-2 or selective Ipamorelin, are short peptides degraded in the gastrointestinal tract and administered parenterally in studies. Both families act on the same receptor (GHS-R1a), but differ in structure, route of administration and pharmacokinetics.
- Secretagogue and SARMs — MK-677 is sometimes mistakenly classified as a SARM due to its presence in similar research catalogues. This is a mechanistic misunderstanding: SARMs (MK-2866, LGD-4033, RAD-140) are selective modulators of the androgen receptor, while MK-677 does not bind the androgen receptor – it acts only through the ghrelin receptor and the GH–IGF-1 axis.
- The context of research security — in the literature on MK-677, possible water retention (related to the GH drive) and impact on the glycemic balance (increase in glycemia and insulin resistance) were reported. These observations are important when designing research models and assessing the compound profile.
This distinction is of both mechanistic and compliance importance: MK-677 is sometimes colloquially called “GH in a tablet” or confused with a SARM, while its pharmacology is different from both of these categories. In anti-doping terms, it remains classified by WADA as a growth hormone (S2) secretagogue – regardless of common associations.
Applications in scientific research
MK-677 is used in research work in several areas. In vivo models (rodents) and phase I/II clinical trials examine its effect on the GH and IGF-1 profile, nitrogen balance, appetite and sleep architecture. In vitro models measure affinity for the ghrelin receptor (GHS-R1a) and characterize the signaling cascade triggered upon its stimulation. As an oral ghrelin mimetic, it is sometimes compared in comparative studies with other compounds from the category growth hormone and IGF-1. Specific research directions include:
- GH–IGF-1 axis — MK-677 as an oral tool for stimulating endogenous GH secretion while maintaining pulsatility, in studies on the regulation of the somatotropic axis
- Ghrelin receptor signaling (GHS-R1a) — characterization of receptor agonism, signaling cascade and pharmacology of ghrelin mimetics
- Models of sarcopenia and catabolism — the impact of GH/IGF-1 drive on anabolic markers, muscle mass and nitrogen balance in research cohorts
- Appetite regulation — orexigenic effect related to ghrelin signaling in energy management models
- Dream architecture — influence on the deep (slow-wave) sleep component, consistent with the role of ghrelin in sleep regulation
- Metabolic safety profile — research on water retention, glycemia and insulin sensitivity as parameters characterizing the relationship
Summary
MK-677 (ibutamoren, 10 mg × 60 capsules) is synthetic non-peptide small molecule from class growth hormone secretagogues, developed in Merck laboratories as an orally active ghrelin mimetic. Its central mechanism is ghrelin receptor agonism (GHS-R1a) — stimulation of the pituitary gland pulsating endogenous GH release, with a secondary increase in IGF-1. It stands out for oral activity and long half-life (~24 h) — unlike peptide GHRPs administered parenterally — and maintaining the physiological pulsatility of secretion, which distinguishes it from exogenous rhGH.
Studies have also observed effects on appetite, deep sleep and nitrogen balance, consistent with ghrelin signaling. MK-677 is a small oral molecule – not a peptide and not an androgenic SARM — works through the ghrelin receptor, not the androgen receptor. This capsule variant is a separate format from the MK-677 30 ml solution. HPLC purity ≥98%, MS, COA for each batch.
Regulatory Status – Research Use Only; lack of EMA/FDA/EFSA authorization (phase II for sarcopenia); WADA Prohibited List, Category S2 (Growth Hormone Secretagogues) – Permanently Prohibited. A practical guide to the oral form of secretagogue and its place in research discusses the entry MK-677 growth hormone in tablets; the broader context of the selection of compounds driving the GH–IGF-1 axis is presented in an overview peptides in bodybuilding.
Bibliography
- Patchett AA, Nargund RP, Tata JR, et al. (1995). Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. PubMed
- Chapman IM, Bach MA, Van Cauter E, et al. (1996). Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretagogue (MK-677) in healthy elderly subjects. PubMed
- Murphy MG, Plunkett LM, Gertz BJ, et al. (1998). MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. PubMed
- Nass R, Pezzoli SS, Oliveri MC, et al. (2008). Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. PubMed
- Adunsky A, Chandler J, Heyden N, et al. (2011). MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled study. PubMed
FAQ
Mechanism and physiology of secretion. A secretagogue like MK-677 stimulates the pituitary gland to release own growth hormone through the ghrelin receptor – while maintaining the pulsatile rhythm of secretion and feedback of the somatotropic axis. Exogenous recombinant rhGH delivers the hormone from the outside, raising its levels rapidly and abolishing the natural rhythm. This is a qualitative difference: one molecule stimulates endogenous production, the other introduces a ready-made hormone. For studies on the regulation of the GH–IGF-1 axis, the preservation of pulsatility makes MK-677 a useful tool.
Only the format of the reagent supplied. The capsule variant is hard capsule 10 mg per capsule, 60 capsules — convenient for handling a weighed portion of powder when preparing individual samples without an analytical balance. The MK-677 liquid 30 ml format is a solution ready for collection. The active substance (ibutamoren, MK-677) and its mechanism (GHS-R1a agonism) remain identical; the only difference is the form and method of preparing the working solution. The choice of format depends on the preferences of the research unit and the nature of the model.
The literature on MK-677 reported two parameters important for the research safety profile: possible water retention (related to the growth hormone drive) and the effect on glycemic management — observed increase in glycemia and insulin sensitivity towards insulin resistance. These are observations that require consideration when designing research models and assessing the compound. They concern the research context and do not constitute information on the use of the RUO reagent in humans.
Yes. MK-677 (ibutamoren) is located on WADA Prohibited List in category S2 (peptide hormones, growth factors, related substances and mimetics), in the growth hormone secretagogue subgroup – permanently prohibited, both in competition and out of competition. Registered Athletes (ADAMS) must absolutely verify the current Prohibited List before making any decision; the presence of ibutamoren or its metabolites in a doping sample results in an anti-doping rule violation.
-
Damian
Szybka wysyłka i pełen profesjonalizm
Paczka była u mnie już na drugi dzień od złożenia zamówienia. Produkt w 100% zgodny z opisem, świetnie zabezpieczony na czas transportu. Zdecydowanie polecam ten sklep.
-
Ewa
Profesjonalna obsługa i wysoka jakość
To już moje kolejne zamówienie w tym sklepie i jak zwykle wszystko na najwyższym poziomie. Produkt dotarł bardzo szybko, starannie zapakowany i z długa datą ważności. Skład czysty, zgodny z opisem producenta na stronie. Widać, że sklep dba o jakość oferowanego asortymentu. Na pewno wrócę po kolejne zakupy, zdecydowanie polecam!
-
Grzegorz
Polski
Bezproblemowy kontakt i natychmiastowa wysyłka
Przed zakupem MK 677 miałem kilka pytań dotyczących samej serii oraz terminu przydatności – obsługa klienta odpisała dosłownie w kilkanaście minut, udzielając wyczerpujących odpowiedzi. Przesyłka dotarła już następnego dnia. Świetny standard obsługi.
-
Jacek UK
Polski
Warto zaufać opiniom
Przeczytałem pozytywne opinie o MK677 na tej stronie i postanowiłem sprawdzić ofertę. Sklep działa niezwykle sprawnie – obsługa odpowiedziała na moje pytania dotyczące składu w kilka minut. Paczka solidnie zapakowana i dyskretna. 5/5!
-
Robert
Polski
Oryginalny produkt z pewnego źródła
Szukałem sprawdzonego sklepu oferującego MK-677 i ten wybór był strzałem w dziesiątkę. Produkt jest oryginalnie zapakowany, posiada czytelny skład i długi termin przydatności. Żadnych wątpliwości co do jakości. Realizacja zamówienia przebiegła błyskawicznie – paczka była w paczkomacie w mniej niż 24 godziny.
-
Adam
Polski
Dziala
Szybką dostawą i dobre dzialanie
-
Karol
Polski Verified purchase
Product review
Polecam.
-
Sławomir
Polski
Product review
Produkt ok, polecam.
-
Marcin G.
Polski Verified purchase
Product review
Polecam produkt, polecam również sprzedającego – pełna profeska i podejście do klienta.
-
maruś
Polski Verified purchase
Product review
Klasa produkt.
-
Karol S.
Polski Verified purchase
Product review
Przypomniało mi się wystawić opinię – bardzo polecam sklep, wysyłka ekspresowa za każdym razem. Takie podejście do klienta bardzo się ceni.
-
Bartek
Polski
Product review
Super produkt.
-
Sajmon
Polski
Product review
Genialny produkt. Super sprawa!